Disparate Midlatitude Responses to the Eastern Pacific El Niño

To investigate the disparate influences of the eastern Pacific (EP) El Niño on the winter climate in the Far East, we conducted composite analyses using long-term reanalysis datasets. Our analysis shows that the western Pacific (WP) pattern dominates in the warm winter (typical) composite and the Pacific–North American (PNA) pattern dominates in the non-warm winter (atypical) composite. In the warm winter case, the amplitudes of the negative sea surface temperature (SST) anomalies in the western Pacific Ocean are large whereas in the non-warm winter case, these amplitudes are small. In addition, the Indian Ocean basin warming occurs following the Indian Ocean dipole mode, as seen in the warm winter composite. We investigated the dynamical mechanisms responsible for the disparate midlatitude responses to the EP El Niño by focusing on Rossby wave sources and propagation. These SST anomalies modulate the Walker and Hadley circulations and the convective activity in the western Pacific Ocean. Upper-tropospheric divergences at the midlatitudes due to the anomalous Hadley circulation result in different teleconnection patterns. In the warm winter composite, the anticyclonic anomaly in the southern part of the WP pattern is created by the upstream negative Rossby wave source, while the other cyclonic anomaly is reinforced by the northward Rossby wave propagation. The cyclonic second and fourth centers of action of the PNA pattern are created by the positive Rossby wave sources. Furthermore, the equatorial SST gradient near the date line is found be a good precursor of the winter climate in the Far East

Association of C-X-C chemokine receptor type 4(CXCR4) expression and clinicopathologic features in human vulvar cancer

application/pdf内容の要旨・審査結果の要旨 / 三重大学大学院医学系研究科生命医科学専攻病態修復医学講座甲女性骨盤外科学分野がんプロフェッショナル養成プラン婦人科腫瘍専門医コー

Association of C-X-C chemokine receptor type 4(CXCR4) expression and clinicopathologic features in human vulvar cancer

application/pdf要約 / 三重大学大学院医学系研究科生命医科学専攻病態修復医学講座女性骨盤外科学分

Snack Texture Estimation System Using a Simple Equipment and Neural Network Model

Texture evaluation is manually performed in general, and such analytical tasks can get cumbersome. In this regard, a neural network model is employed in this study. This paper describes a system that can estimate the food texture of snacks. The system comprises a simple equipment unit and an artificial neural network model. The equipment simultaneously examines the load and sound when a snack is pressed. The neural network model analyzes the load change and sound signals and then outputs a numerical value within the range (0,1) to express the level of textures such as “crunchiness” and “crispness”. Experimental results validate the model’s capacity to output moderate texture values of the snacks. In addition, we applied the convolutional neural network (CNN) model to classify snacks and the capability of the CNN model for texture estimation is discussed

A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer

Abstract Introduction Bevacizumab and gemcitabine are key drugs for treating recurrent epithelial ovarian cancer. However, information about the combination of bevacizumab and gemcitabine is insufficient. We conducted a phase II study to assess the feasibility, clinical activity, and toxicity of this combination chemotherapy. Methods This study included women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer who received one to three regimens of platinum-based chemotherapy between April 1, 2015 and December 31, 2018. The patients received bevacizumab 15 mg/kg intravenously on day 1 and gemcitabine 1000 mg/m2 intravenously on days 1 and 8 every 21 days until disease progression or unacceptable toxicity. The primary endpoint was the completion rate of three cycles of chemotherapy. This study was registered in the University Medical Information Network (UMIN) Clinical Trials Registry (UMIN000016619). Results Among the 19 patients, 18 (95%) received ≥3 and 9 (47%) received ≥6 cycles of the study therapy. The objective response rate was 42% (complete response of 16% and partial response of 26%), and the clinical control rate was 84%. Hematological toxicity included neutropenia grade 3/4 in 9 patients (47%), anemia grade 3/4 in 2 (11%), and thrombocytopenia grade 3/4 in 1 (5%). One patient (5%) had grade 3 hypertension, and 1 (5%) had grade 3 protein urea. Possibly related grade 3 pulmonary toxicity was observed in 1 patient. Three patients needed dose reduction of gemcitabine to 800 mg/m2 due to treatment delay by 15 to 21 days on day1. There was no treatment delay more than 14 days on day 8. The median progression-free survival duration was 5.1 months and median overall survival duration was 21.3 months. Conclusion The combination chemotherapy with gemcitabine and bevacizumab was feasible, effective and safe. This combination chemotherapy may be explored in a further randomized trial